Fibroblast growth factor 2 internal ribosome entry site (IRES) activity ex vivo and in transgenic mice reveals a stringent tissue-specific regulationRole of hypoxia and vascular endothelial growth factors in lymphangiogenesisPromoter-Dependent Translation Controlled by p54nrb and hnRNPM during Myoblast DifferentiationPyrimidine tract binding protein and La autoantigen interact differently with the 5' untranslated regions of lentiviruses and oncoretrovirus mRNAs.Long term expression of bicistronic vector driven by the FGF-1 IRES in mouse muscleFGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha.IRES-based vector coexpressing FGF2 and Cyr61 provides synergistic and safe therapeutics of lower limb ischemia.Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells.Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site.p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damagep53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.Therapeutic Benefits and Adverse Effects of Combined Proangiogenic Gene Therapy in Mouse Critical Leg Ischemia.Fibroblast growth factor 1 induced during myogenesis by a transcription-translation coupling mechanism.Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose metabolism in the onset of diabetes.Dachsous1-Fat4 Signaling Controls Endothelial Cell Polarization During Lymphatic Valve Morphogenesis-Brief Report.Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1α-independent translation-mediated mechanism.p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer.The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression.Unr is required in vivo for efficient initiation of translation from the internal ribosome entry sites of both rhinovirus and poliovirus.Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES.Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarctionA single internal ribosome entry site containing a G quartet RNA structure drives fibroblast growth factor 2 gene expression at four alternative translation initiation codons.New ways of initiating translation in eukaryotes.Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site.Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.Local production of tenascin-C acts as a trigger for monocyte/macrophage recruitment that provokes cardiac dysfunction.Low dietary inorganic phosphate affects the brain by controlling apoptosis, cell cycle and protein translation.Nucleolin Promotes Heat Shock-Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis.Lymphatic Vasculature Requires ER (Estrogen Receptor)-α Signaling to Protect From Lymphedema.Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression.Translation of the human c-myc P0 tricistronic mRNA involves two independent internal ribosome entry sites.IRES Trans-Acting Factors, Key Actors of the Stress ResponseA high inorganic phosphate diet perturbs brain growth, alters Akt-ERK signaling, and results in changes in cap-dependent translationVasohibin1, a new mouse cardiomyocyte IRES trans-acting factor that regulates translation in early hypoxia[Lymphangiogenic gene expression adaptation in tumor hypoxic environment]Paclitaxel induces lymphatic endothelial cells autophagy to promote metastasisA plasmid vector allowing positive selection of recombinant plasmids in Streptococcus pneumoniae
P50
Q24683914-950E05E2-5E99-4A63-8D82-80FA7F217D3AQ26745683-72AB1C23-D5AE-4113-925F-C4D2CE03A7DDQ28547716-6B6C3691-B099-40CD-AB94-1383DD473150Q31924399-674FD3B1-0210-42D4-BC89-0B2187CFC947Q33304058-6134978E-734C-40E2-B4EB-E7823F7D20BAQ33363570-922A16C8-EA83-4CB1-90BA-518D8052B099Q33500964-8EBEA639-AA98-4D11-9657-BF42F9D109F6Q33506633-F88D73DE-4343-4133-9980-E40C56391436Q34065706-7EC44697-48BE-4F9D-8E20-3155700C3498Q34575503-F63E8FC4-0F54-4901-8351-FD9B43B94BC7Q35029530-CA5E6EDA-3B1F-43C8-993E-38B74E71B659Q36208654-DF3729D4-3E62-4431-8265-422C7F7F3ACCQ37384774-7BCACB9F-240A-4A18-995E-F10D82AABAF0Q37513099-8719409B-F847-4FDD-88F8-10989037E863Q38680166-A5B1DDC2-213B-4FC5-95BD-BC0C69803654Q39037560-B6226BCD-CCE0-4790-BB04-77FC8049A125Q39096715-CE135044-3568-4635-9C9E-15F7EC2F54C4Q39325284-08342C96-8447-4820-8BAF-B51F82E1D3D3Q39732468-A9DBD916-748E-4E47-A8CA-9B24351D222EQ39998139-8E3559D3-796C-4314-A2BE-2D8849F42D2EQ42126369-6F178A5A-A6CA-4C05-B4CF-6977089E806FQ42150691-0B1278DA-E7A3-478E-86CB-5E4AFF7E0D90Q42738018-B3819A3A-F907-4D30-83A1-F57CBE895112Q45004100-3E919D6E-21D1-4473-B07A-D32DC6901BD7Q47295524-B1B530B5-8DDA-4982-8BC4-9752D21C2025Q47405015-92916FBE-FFB7-4827-9652-CED4D04631E0Q48164338-526C0C94-A58D-448C-BE04-D5D0FD6CFBE4Q51712051-1F3B9CB2-2327-48E2-9329-203D89A3CA84Q52591092-8508B364-1819-4206-A9E1-35EAF26E831AQ53697011-D2F777BE-F2EC-4B72-AF13-0269B0FBF84CQ53888869-B0450E07-00EA-4103-AE59-2931DABB405CQ64258342-8FD3B86E-668D-4E0A-9812-2B224B6113FFQ81597356-144884A7-6F1B-4614-83CB-D5D19E14C718Q83225184-71AA4539-5B8B-4738-B759-C421C7D93A14Q88100233-7D74823A-C101-46E0-93FC-8509F8756F10Q92163838-1EA10972-2841-43BB-B8BB-3D868D9FC283Q93659777-A5413A5D-A51E-4E68-B7D7-38BD5ABF64B3
P50
description
Frans onderzoekster
@nl
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Anne-Catherine Prats
@ast
Anne-Catherine Prats
@en
Anne-Catherine Prats
@es
Anne-Catherine Prats
@fr
Anne-Catherine Prats
@nl
Anne-Catherine Prats
@sl
type
label
Anne-Catherine Prats
@ast
Anne-Catherine Prats
@en
Anne-Catherine Prats
@es
Anne-Catherine Prats
@fr
Anne-Catherine Prats
@nl
Anne-Catherine Prats
@sl
prefLabel
Anne-Catherine Prats
@ast
Anne-Catherine Prats
@en
Anne-Catherine Prats
@es
Anne-Catherine Prats
@fr
Anne-Catherine Prats
@nl
Anne-Catherine Prats
@sl
P1053
E-5051-2016
P106
P21
P27
P31
P496
0000-0002-5282-3776
P569
1961-05-05T00:00:00Z
P6634
anne-catherine-prats-77bb8685